GMED:NYE-Globus Medical (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 75.07

Change

+0.78 (+1.05)%

Market Cap

USD 10.01B

Volume

0.86M

Analyst Target

USD 60.85
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.05 (+0.93%)

USD 199.13B
MDT Medtronic PLC

+0.18 (+0.20%)

USD 118.35B
STE STERIS plc

+0.52 (+0.23%)

USD 21.85B
ZBH Zimmer Biomet Holdings Inc

+5.93 (+5.71%)

USD 21.23B
SNN Smith & Nephew SNATS Inc

-0.02 (-0.07%)

USD 12.71B
BIO Bio-Rad Laboratories Inc

-1.06 (-0.32%)

USD 9.26B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.19B
PEN Penumbra Inc

+1.66 (+0.79%)

USD 7.95B
GKOS Glaukos Corp

+0.93 (+0.68%)

USD 7.18B
INSP Inspire Medical Systems Inc

-2.54 (-1.28%)

USD 5.82B

ETFs Containing GMED

CIB0:XETRA VanEck Bionic Engineering.. 3.50 % 0.00 %

-0.18 (-0.11%)

USD 5.03M
CYBG:LSE VanEck Bionic Engineering.. 3.35 % 0.00 %

-0.02 (-0.11%)

N/A
EASI 2.82 % 0.75 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 1.94 % 0.35 %

+0.24 (+-0.11%)

USD 0.21B
GGEM:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.87% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.87% 81% B- 88% B+
Trailing 12 Months  
Capital Gain 63.23% 77% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.23% 77% C+ 87% B+
Trailing 5 Years  
Capital Gain 44.34% 75% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.34% 75% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.98% 55% F 60% D-
Dividend Return 6.98% 55% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.14% 74% C 39% F
Risk Adjusted Return 25.73% 55% F 42% F
Market Capitalization 10.01B 81% B- 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.